Cell-based screening in antibacterial discovery

Antibiotic Discovery and Development

Volumn 9781461414001, Issue , 2012, Pages 901-929

  Mills, Scott D ^a   Dougherty, Thomas J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949178337     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1400-1_28     Document Type: Chapter

References (85)

1. Fleming A (1929) On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Brit J Exper Pathol 10:226-236
2. Waksman SA, Woodruff HB (1940) The soil as a source of microorganisms antagonistic to disease-producing bacteria. J Bacteriol 40:581-600
3. Domagk G (1952) Further progress in chemotherapy of bacterial infections From Nobel Lectures, Physiology or Medicine 1922-1941. Elsevier, Amsterdam, 1965
4. Raju T (1999) The Nobel chronicles. 1939: Gerhard Domagk (1895-1964). Lancet 353:681
5. Geddes A (2008) 80th Anniversary of the discovery of penicillin: an appreciation of Sir Alexander Fleming. Int J Antimicrob Agents 32:373
6. Moyer AJ, Goghill RD (1946) Penicillin: IX. The laboratory scale production of penicillin in submerged cultures by Penicillium notatum Westling (NRRL 832). J Bacteriol 51:79-93
7. Schatz A, Bugie E, Waksman SA (1944) Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram negative bacteria. Proc Exptl Biol Med 55:66-69
8. Waksman S (1964) Streptomycin: background, isolation, properties, and utilization Nobel Lecture, December 12, 1952 From Nobel Lectures, Physiology or Medicine 1942-1962. Elsevier, Amsterdam
9. Umezawa H (1958) Kanamycin: its discovery. Ann N Y Acad Sci 76:20-26
10. Waksman SA, Lechevalier HA (1949) Neomycin, a new antibiotic active against streptomycin- resistant bacteria, including tuberculosis organisms. Science 109:305-307
11. Duggar BM (1948) Aureomycin; a product of the continuing search for new antibiotics. Ann N Y Acad Sci 51:177-181
12. Finlay AC, Hobby GL (1950) Terramycin, a new antibiotic. Science 111:85
13. Ehrlich J, Gottlieb D, Burkholder PR et al (1948) Streptomyces venezuelae, N. Sp., the source of chloromycetin. J Bacteriol 56:467-477
14. Harned RL, Hidy PH, La Baw EK (1955) Cycloserine. 1. A preliminaryreport. Antibiot Chemother 5:204-205
15. Sensi P, Timbal MT, Greco AM (1962) Rifamycin. XXVI. Derivatives of rifamycin O with high antimicrobial activity. Antibiot Chemother 12:488-494
16. Anderson RC, Griffith RS, Higgins HM et al (1961) How a drug is born. Cincinnati J Med 42:49-60
17. Conover LH (1971) Discovery of drugs from microbiological sources. Adv Chem Drug Discov Ch 3:33-80
18. Spellberg B, Powers JH, Brass EP et al (2004) Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38:1279-1286
19. Payne DJ, Gwynn MN, Holmes DJ et al (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6:29-40
20. Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12
21. Lipinski CA, Lombardo F, Dominy BW et al (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Del Rev 23:3-25
22. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6:881-890
23. Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249
24. O'Shea R, Moser HE (2008) Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 51:2871-2878
25. Davies J (2008) Resistance redux. Infectious diseases, antibiotic resistance and the future of mankind. EMBO Rep. 9 Suppl 1:S18-21
26. Baltz RH (2006) Marcel Faber Roundtable: is our antibiotic pipeline unproductive because of starvation, constipation or lack of inspiration? J Ind Microbiol Biotechnol 33:507-513
27. De La Fuente R, Sonawane ND, Arumainayagam D et al (2006) Small molecules with antimicrobial activity against E. coli and P. aeruginosa identified by high-throughput screening. Br J Pharmacol 149:551-559
28. Gabrielson J, Hart M, Jarelöv A et al (2002) Evaluation of redox indicators and the use of digital scanners and spectrophotometer for quantification of microbial growth in microplates. J Microbiol Methods 50:63-73
29. Schneider T, Sahl HG (2010) An oldie but a goodie - cell wall biosynthesis as antibiotic target pathway. Int J Med Microbiol 300:161-169
30. Aoki H, Sakai H, Kohsaka M et al (1976) Nocardicin A, a new monocyclic b -lactam antibiotic. I. Discovery, isolation and characterization. J Antibiot 29:492-500
31. Kitano K, Nara K, Nakao Y (1977) Screening for b -lactam antibiotics using a mutant of Pseudomonas aeruginosa. J Antibiot 30:239-245
32. Kamogashira T (1988) Some characteristics of a hypersensitive mutant to b -lactam antibiotics derived from a strain of Staphylococcus aureus. Agric Biol Chem 52:1841-1843
33. Kamogashira T, Takegata S (1988) A screening method for cell wall inhibitors using a D-cycloserine hypersensitive mutant. J Antibiot 41:803-806
34. Gadebusch HH, Stapley EO, Zimmerman SB (1992) The discovery of cell wall active antibacterial antibiotics. Crit Rev Biotechnol 12:225-243
35. Kahan JS, Kahan FM, Goegelman R et al (1979) Thienamycin, a new p-lactam antibiotic. I. Discovery, taxonomy and physical properties. J Antibiot 32:1-12
36. Imada A, Kitano K, Kintaka K et al (1981) Sulfazecin and isosulfazecin, novel b -lactam antibiotics of bacterial origin. Nature 289:590-591
37. Sykes RB, Cimarusti CM, Bonner DP et al (1981) Monocyclic b -lactam antibiotics produced by bacteria. Nature 291:489-491
38. Sykes RB, Bonner DP, Bush K et al (1982) Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother 21:85-92
39. Nozaki Y, Katayama N, Ono H (1987) Binding of a non- b -lactam antibiotic to penicillinbinding proteins. Nature 325:179-180
40. Nozaki Y, Katayama N, Harada S et al (1989) Lactivicin, a naturally occurring non- b -lactam antibiotic having b -lactam-like action: biological activities and mode of action. J Antibiot 42:84-93
41. Mardones G, Venegas A (2000) Chromogenic plate assay distinguishing bacteriolytic from bacteriostatic activity of an antibiotic agent. J Microbiol Methods 40:199-206
42. Falk SP, Ulijasz AT, Weisblum B (2007) Differential assay for high-throughput screening of antibacterial compounds. J Biomol Screen 12:1102-1108
43. O'Sullivan J, McCullough JE, Tymiak AA et al (1988) Lysobactin, a novel antibacterial agent produced by Lysobacter sp. I. Taxonomy, isolation and partial characterization. J Antibiot 41:1740-1744
44. Rake JB, Gerber R, Mehta RJ et al (1986) Glycopeptide antibiotics: a mechanism-based screen employing a bacterial cell wall receptor mimetic. J Antibiot 39:58-67
45. Riva E, Gastaldo L, Beretta MG et al (1989) A42867, a novel glycopeptide antibiotic. J Antibiot 42:497-505
46. DeCenzo M, Kuranda M, Cohen S et al (2002) Identification of compounds that inhibit late steps of peptidoglycan synthesis in bacteria. J Antibiot 55:288-295
47. Oyamada Y, Ito H, Fujimoto-Nakamura M et al (2006) Anucleate cell blue assay: a useful tool for identifying novel type II topoisomerase inhibitors. Antimicrob Agents Chemother 50:348-350
48. Gitai Z, Dye NA, Reisenauer A et al (2005) MreB actin-mediated segregation of a specific region of a bacterial chromosome. Cell 120:329-341
49. Iwai N, Nagai K, Wachi M (2002) Novel S-benzylisothiourea compound that induces spherical cells in Escherichia coli probably by acting on a rod-shape-determining protein(s) other than penicillin-binding protein 2. Biosci Biotechnol Biochem 66:2658-2662
50. Fossum S, De Pascale G, Weigel C et al (2008) A robust screen for novel antibiotics: specific knockout of the initiator of bacterial DNA replication. FEMS Microbiol Lett 281: 210-214
51. Young K, Silver LL, Bramhill D et al (270) The envA permeability/cell division gene of Escherichia coli encodes the second enzyme of lipid A biosynthesis. UDP-3-O-(R-3- hydroxymyristoyl)-N-acetylglucosamine deacetylase. J Biol Chem 270:30384-30391
52. Clements JM, Coignard F, Johnson I et al (2002) Antibacterial activities and characterization of novel inhibitors of LpxC. Antimicrob Agents Chemother 46:1793-1799
53. Tamae C, Liu A, Kim K et al (2008) Determination of antibiotic hypersensitivity among 4000 single gene knockout mutants of Escherichia coli. J Bacteriol 190:5981-5988
54. Vertommen D, Ruiz N, Leverrier P et al (2009) Characterization of the role of the Escherichia coli periplasmic chaperone SurA using differential proteomics. Proteomics 9:2432-2443
55. DeVito JA, Mills JA, Liu VG et al (2002) An array of target-specific screening strains for antibacterial discovery. Nat Biotechnol 20:478-483
56. Ji Y, Zhang B, Van SF et al (2001) Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 293:2266-2299
57. Forsyth RA, Haselbeck RJ, Ohlsen KL et al (2002) A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol Microbiol 43:1387-1400
58. Young K, Jayasuriya H, Ondeyka JG et al (2006) Discovery of FabH/FabF inhibitors from natural products. Antimicrob Agents Cheother 50:519-526
59. Singh SB, Jayasuriya H, Ondeyka JG (2006) Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. J Am Chem Soc 128:11916-11920
60. Wang J, Kodali S, Lee SH et al (2007) Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci USA 104:7612-7616
61. Cronan JE (2003) Bacterial membrane lipids: where do we stand? Ann Rev Microbiol 57:203-224
62. Kedar GC, Brown-Driver V, Reyes DR et al (2007) Evaluation of the metS and murB loci for antibiotic discovery using targeted antisense RNA expression analysis in Bacillus anthracis. Antimicrob Agents Chemother 51:1708-1718
63. Kedar GC, Brown-Driver V, Reyes DR et al (2008) Comparison of the essential cellular functions of the two murA genes of Bacillus anthracis. Antimicrob Agents Chemother 52: 2009-2013
64. Donald RG, Skwish S, Forsyth RA et al (2009) A Staphylococcus aureus fitness test platform for mechanism-based profiling of antibacterial compounds. Chem Biol 16:826-836
65. Richmond CS, Glasner JD, Mau R et al (1999) Genome-wide expression profiling in Escherichia coli K-12. Nucleic Acids Res 27:3821-3835
66. Gmuender H, Kuratli K, Di Padova K et al (2001) Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis. Genome Res 11:28-42
67. Sabina J, Dover N, Templeton LJ et al (2003) Interfering with different steps of protein synthesis explored by transcriptional profiling of Escherichia coli K-12. J Bacteriol 185:6158-6170
68. Shaw KJ, Miller N, Liu X et al (2003) Comparison of the changes in global gene expression of Escherichia coli induced by four bactericidal agents. J Mol Microbiol Biotechnol 5:105-122
69. Frieberg C, Fischer HP, Brunner NA (2005) Discovering the mechanism of action of novel antibacterial agents through transcriptional profiling of conditional mutants. Antimicrob Agents Chemother 49:749-759
70. Fischer HP, Brunner NA, Wieland B et al (2004) Identification of antibiotic stress-inducible promoters: a systematic approach to novel pathway-specific reporter assays for antibacterial drug discovery. Genome Res 14:90-98
71. Yagi K (2007) Applications of whole-cell bacterial sensors in biotechnology and environmental science. Appl Microbiol Biotechnol 73:1251-1258
72. Goh EB, Yim G, Tsui W et al (2002) Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics. Proc Natl Acad Sci USA 99:17025-17030
73. Shapiro E, Baneyx F (2007) Stress-activated bioluminescent Escherichia coli sensors for antimicrobial agents detection. J Biotechnol 132:487-493
74. Bianchi A, Baneyx F (1999) Stress responses as a tool to detect and characterize the mode of action of antibacterial agents. Appl Environ Microbiol 65:5023-5027
75. Hansen LH, Sörensen SJ (2000) Detection and quantification of tetracyclines by whole cell biosensors. FEMS Microbiol Lett 190:273-278
76. Hutter B, Fischer C, Jacobi A et al (2004) Panel of Bacillus subtilis reporter strains indicative of various modes of action. Antimicrob Agents Chemother 48:2588-2594
77. Urban A, Eckermann S, Fast B et al (2007) Novel whole-cell antibiotic biosensors for compound discovery. Appl Environ Microbiol 73:6436-6443
78. Hutter B, Schaab C, Albrecht S et al (2004) Prediction of mechanisms of action of antibacterial compounds by gene expression profiling. Antimicrob Agents Chemother 48:2838-2844
79. Shapiro E, Baneyx F (2002) Stress-based identification and classification of antibacterial agents: second-generation Escherichia coli reporter strains and optimization of detection. Antimicrob Agents Chemother 46:2490-2497
80. Shapiro E, Lu C, Baneyx F (2005) A set of multicolored Photinus pyralis luciferase mutants for in vivo bioluminescence applications. Protein Eng Des Sel 18:581-587
81. Mills SD, Yang W, MacCormack K (2004) Molecular characterization of benzimidazole resistance in Helicobacter pylori. Antimicrob Agents Chemother 48:2524-2530
82. Brötz-Oesterhelt H, Beyer D, Kroll H-P et al (2005) Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med 11:1082-1087
83. Belanger AE, Lai A, Brackman MA et al (2002) PCR-based ordered genomic libraries: a new approach to drug target identification for Streptococcus pneumoniae. Antimicrob Agents Chemother 46:2507-2512
84. Li X, Zolli-Juran M, Cechetto JD, Daigle DM et al (2004) Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. Chem Biol 11: 1423-1430
85. Miller AA, Bundy GL, Mott JE et al (2008) Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob Agents Chemother 52:2806-2812